Reform Dynamics | Biomedicine and Health
Release time:
2024-09-03
Enhance the level of industrial development. Develop specialized pharmaceutical parks, support the formation of industrial alliances or consortiums, and build an innovation-driven, green low-carbon, and intelligent efficient advanced manufacturing system to improve industrial concentration and enhance the supply capacity of mid-to-high-end products.
Strengthen innovation in medical technology. Improve the collaborative innovation system among government, industry, academia, research, and application to promote pharmaceutical innovation and transformation upgrades. Enhance the innovation capabilities of patented drugs, new traditional Chinese medicines, new formulations, and high-end medical devices, and promote the generic market entry of patented drugs for major diseases upon patent expiration. Vigorously develop new varieties of biopharmaceuticals, chemical drugs, high-quality traditional Chinese medicines, high-performance medical devices, new auxiliary materials and packaging, and pharmaceutical equipment to promote the industrialization of major drugs, accelerate the transformation and upgrading of medical devices, and improve the international competitiveness of medical diagnostic equipment and medical materials with independent intellectual property rights. Accelerate the development of the rehabilitation assistive device industry and enhance independent innovation capabilities. Improve the quality standard system, enhance quality control technology, implement green and intelligent transformation upgrades, and by 2030, ensure that drug and medical device quality standards are fully aligned with international standards.
Enhance the level of industrial development. Develop specialized pharmaceutical parks, support the formation of industrial alliances or consortiums, build an advanced manufacturing system driven by innovation, green low-carbon practices, and intelligent efficiency to increase industry concentration and enhance the supply capacity of mid-to-high-end products.
Tag:
Share
